Aligning payer and provider strategies with the latest evidence to optimize clinical outcomes for patients with neuromyelitis optica spectrum disorder

Social Sciences

• clinical outcomes 99%
• evidence 31%
• early diagnosis 15%
• need for care 14%
• disability 14%
• appropriate treatment 14%
• treatment decisions 14%
• multiple sclerosis 14%
• knowledge gap 12%
• managed care 12%
• hospitalization 11%
• Health Care Providers 11%
• morbidity 10%
• management 10%
• mortality 8%
• quality of life 8%
• water 8%
• stakeholder 7%
• decision making 6%
• costs 5%
• economics 4%
• experience 3%

Medicine & Life Sciences

• Neuromyelitis Optica 100%
• Immunoglobulin G 14%
• Therapeutics 12%
• Myelin-Oligodendrocyte Glycoprotein 8%
• Aquaporin 4 8%
• Aquaporins 7%
• Managed Care Programs 7%
• Symptom Flare Up 7%
• Antibodies 6%
• Time-to-Treatment 6%
• Central Nervous System Diseases 6%
• Ambulatory Care 6%
• Multiple Sclerosis 5%
• Health Personnel 5%
• Autoimmune Diseases 5%
• Decision Making 5%
• Early Diagnosis 5%
• Economics 4%
• Central Nervous System 4%
• Hospitalization 4%
• Monoclonal Antibodies 4%
• Magnetic Resonance Imaging 4%
• Quality of Life 3%
• Costs and Cost Analysis 3%
• Morbidity 3%
• Safety 3%
• Mortality 3%

Chemical Compounds

• Disorder 63%
• Glycoprotein 6%
• Safety 5%
• Protein 2%